Top

Japanese Encephalitis Vaccine (JEV)

Active

SPE2DP-23-R-0001Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The Defense Logistics Agency Troop Support is seeking proposals for the supply of the Japanese Encephalitis Vaccine (JEV), a purified, inactivated, Vero Cell culture-derived vaccine designed for active immunization against Japanese Encephalitis disease. The vaccine must be FDA-licensed, Thimerosal and preservative-free, latex-free, suitable for intramuscular use, and administered as a sterile 0.5 ml suspension in a pre-filled Type 1 glass syringe with a chlorobutyl elastomer plunger stopper, with or without a separate needle. It must be approved for use in individuals aged two months and older. The contract will be a one-year firm-fixed price indefinite quantity agreement with a minimum order of 201,600 doses and a maximum order of 300,160 doses, all to be delivered FOB destination to the Defense Distribution Depot Susquehanna within 120 days of the delivery order. Solicitations under reference SPE2DP-23-R-0001 are expected to be issued on or after July 14, 2023, and can be accessed through the DLA Internet Bid Board System. Only one responsible source with FDA approval to sell the vaccine will be considered for award, and all responsible sources are invited to submit proposals. The point of contact for this procurement is Danielle Delaney of DLA Troop Support-FSA. The procurement is conducted under the authority of 10 U.S.C. 2034 (c) 1. The requirement falls under NAICS code 325414, and the contract award will support delivering critical vaccine doses for defense personnel.

General Info

DLA seeks FDA-licensed Japanese Encephalitis Vaccine, 201,600-300,160 doses, one-year contract.

Agency

Department Of Defense → DLA Troop Support

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

1 update

PhasePresolicitation

PostedApr 21

Sources Sought

Notice updatedMay 3

The notice description changed.

Type ChangedJul 13

Sources Sought → Presolicitation

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Defense → DLA Troop Support

Contacts1 person available

OfficePHILADELPHIA, PA, 19111, USA

Organization / AgencyDepartment Of Defense → DLA Troop Support

Office AddressPHILADELPHIA, PA, 19111, USA

Contacts

Danielle Delaney

contact@example.gov

Full Description

The Defense Logistics Agency Troop Support has a requirement for the supply of Japanese Encephalitis Vaccine (JEV), NSN 6505-01-607-7018. The vaccine shall be purified, inactivated, Vero Cell culture derived, contain no stabilizers, Thimerosal/Preservative free, Latex free, licensed by the Food and Drug Administration (FDA), suitable for intramuscular administration and intended for active immunization against Japanese Encephalitis disease. The vaccine shall be a sterile 0.5 ml suspension in a pre-filled syringe (Type 1 glass) with a plunger stopper (chlorobutyl elastomer) with or without a separate needle. The vaccine must be approved by the United States FDA for administration to persons 2 months and up. The proposed contract will be a one (1) year base firm-fixed price indefinite quantity contract. The requirement for the base year is 201,600 doses minimum and a maximum of 300,160 doses. Ordered quantities shall be delivered to the Defense Distribution Depot Susquehanna. Delivery is to be FOB Destination and delivered within 120 days from date of the delivery order. All responsible sources may submit a proposal and shall be considered by the Agency. The successful contractor shall have FDA approval to sell JEV before award of the contract. Solicitation SPE2DP-23-R-0001 is expected to be issued on or after July 14, 2023 and can be found on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. The point of contact is Danielle Delaney, DLA Troop Support-FSA, 215-737-2998. The Solicitation will be issued under authority 10 U.S.C. 2034 (c) 1, only one responsible source.